Meta-analysis. Grade I-II

Study	Intervention	Controls	Odds ratio	95% CI	z	P
Stelloo et al. 2016	135/219	589/615	0.0709	0.0440 to 0.114		
An et al. 2007	12/17	64/69	0.188	0.0470 to 0.749		
Black et al. 2006	72/93	267/380	1.451	0.851 to 2.474		
Kommoss et al. 2018	102/127	255/325	1.120	0.672 to 1.867		
Mackay et al. 2010	21/32	21/126	9.545	4.011 to 22.716		
Djordjevic et al. 2013	28/46	50/64	0.436	0.188 to 1.007		
Ruiz et al. 2014	58/64	131/148	1.254	0.470 to 3.345		
Talhouk et al. 2016	10/16	23/41	1.304	0.399 to 4.267		
Talhouk et al. 2017	12/64	111/255	0.299	0.152 to 0.588		
Total (fixed effects)	450/678	1511/2023	0.559	0.456 to 0.684	-5.647	<0.001
Total (random effects)	450/678	1511/2023	0.706	0.257 to 1.940	-0.675	0.500

Q	142.778
DF	8
Significance level	P < 0.001
I² (inconsistency)	94.400%
95% CI for I²	91.36 to 96.37

(A)

Meta-analysis. GIII odd ratio

Study	Intervention	Controls	Odds ratio	95% CI	z	P
Stelloo et al. 2016	36/219	74/615	1.438	0.934 to 2.216		
An et al. 2007	5/17	5/69	5.333	1.336 to 21.295		
Black et al. 2006	21/93	113/380	0.689	0.404 to 1.175		
Djordjevic et al. 2013	8/46	8/64	1.474	0.509 to 4.267		
Ruiz et al. 2014	5/64	17/148	0.653	0.230 to 1.854		
Talhouk et al. 2016	6/16	18/41	0.767	0.234 to 2.508		
Talhouk et al. 2017	52/64	144/255	3.340	1.701 to 6.559		
Total (fixed effects)	133/519	379/1572	1.327	1.028 to 1.711	2.176	0.030
Total (random effects)	133/519	379/1572	1.384	0.806 to 2.375	1.178	0.239

Q	19.629
DF	6
Significance level	P = 0.003
I² (inconsistency)	69.43%
95% CI for I²	32.80 to 86.10

(B)

Supplementary Fig. S10. Pooled odd ratio of tumor grade in mismatch repair (MMR) deficiency in endometrial carcinoma (EC) vs. proficient MMR EC [2,3,13,15,16,18,19,21,24,25]: (A) grade I-II and (B) grade III. CI, confidence interval.